Compare CAVA Group Inc (CAVA) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CAVA Group Inc vs Quest Diagnostics Inc — how do they compare? CAVA Group Inc trades at $68.67 (market cap $7.08B), while Quest Diagnostics Inc trades at $237.43 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× CAVA Group Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| CAVA | DGX | |
|---|---|---|
Market Cap | $7.08B | $26.21B |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $238.50 |
52-Week Low | $43.59 | $173.49 |
Enterprise Value | $7.23B | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $69.68, up 13.15% with strong Q2 2026 earnings beats and 31.3% revenue growth. Technicals are bearish with support at $58, while fundamentals show high P/E of 108.59 but robust same-store sales. News highlights include menu innovation driving traffic and earnings outperformance.
Outlook is positive with a $89.75 consensus price target and 76% buy ratings, though valuation and net cash outflows pose risks. Growth momentum from new restaurants and consumer demand supports upside, but margin pressure and competition require monitoring.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
